amgens finance chief quits associated press thousand oaks calif amgen inc chief financial officer richard nanula announced his resignation amid the biotechnology companys continuing struggles with drug development setbacks and pressure to contain the costs of its expensive drugs amgen is also the target of an informal securities and exchange commission inquiry into its handling of a failed dutch study testing its drug aranesp in patients with anemia caused by cancer the study was stopped in december but amgen didnt publicly disclose its failure until february amgen said mr nanula is leaving to "pursue other opportunities" and will be succeeded by robert bradway years old and a vice president in charge of operations mr nanula will stay on for days to help with the transition he couldnt be reached for comment 
